Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy

被引:38
作者
Dobson, Nicole R. [1 ]
Liu, Xiaoxi [2 ]
Rhein, Lawrence M. [3 ]
Darnall, Robert A. [4 ]
Corwin, Michael J. [5 ]
McEntire, Betty L. [6 ]
Ward, Robert M. [2 ]
James, Laura P. [7 ]
Sherwin, Catherine M. T. [2 ]
Heeren, Timothy C. [8 ]
Hunt, Carl E. [9 ,10 ]
机构
[1] Tripler Army Med Ctr, Pediat, Honolulu, HI 96859 USA
[2] Univ Utah, Sch Med, Clin Pharmacol, Pediat, Salt Lake City, UT USA
[3] Boston Childrens Hosp, Newborn Med & Resp Dis, Boston, MA USA
[4] Geisel Sch Med Dartmouth, Lebanon, NH USA
[5] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA
[6] Amer SIDS Inst, Naples, FL USA
[7] Univ Arkansas, Pediat, Little Rock, AR 72204 USA
[8] Boston Univ, Sch Publ Hlth, Biostat, Boston, MA USA
[9] Uniformed Serv Univ Hlth Sci, Pediat, Bethesda, MD USA
[10] George Washington Univ, Pediat, Washington, DC USA
关键词
caffeine; pharmacokinetic model; preterm infant; saliva; PREMATURE-INFANTS; POPULATION PHARMACOKINETICS; INTRAVENOUS CAFFEINE; DRUG CONCENTRATION; SERUM CAFFEINE; APNEA; MILK; METHYLXANTHINES; THEOPHYLLINE; TRIAL;
D O I
10.1111/bcp.13001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimsCaffeine concentrations in preterm infants are usually measured in the blood. However, salivary assays may provide a valid and practical alternative. The present study explored the validity and clinical utility of salivary caffeine concentrations as an alternative to blood concentrations and developed a novel plasma/salivary caffeine distribution model. MethodsPaired salivary and plasma samples were obtained in 29 infants. Salivary samples were obtained using a commercially available salivary collection system. Caffeine concentrations in the saliva and plasma were determined using high-performance liquid chromatography. A population pharmacokinetic (PK) model was developed using NONMEM 7.3. ResultsThe mean ( standard deviation) gestational age (GA) at birth and birth weight were 27.9 +/- 2.1weeks and 1171.6 +/- 384.9g, respectively. Paired samples were obtained at a mean postmenstrual age (PMA) of 35.5 +/- 1.1weeks. The range of plasma caffeine concentrations was 9.5-54.1gml(-1), with a mean difference (95% confidence interval) between plasma and salivary concentrations of -0.18gml(-1) (-1.90, 1.54). Salivary and plasma caffeine concentrations were strongly correlated (Pearson's correlation coefficient=0.87, P<0.001). Caffeine PK in plasma and saliva was simultaneously described by a three-compartment recirculation model. Current body weight, birth weight, GA, PMA and postnatal age were not significantly correlated with any PK parameter. ConclusionsSalivary sampling provides an easy, non-invasive method for measuring caffeine concentrations. Salivary concentrations correlate highly with plasma concentrations. Caffeine PK in saliva and plasma are well described by a three-compartment recirculation model.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 31 条
[1]   Serum caffeine concentrations and short-term outcomes in premature infants of ≤ 29 weeks of gestation [J].
Alur, P. ;
Bollampalli, V. ;
Bell, T. ;
Hussain, N. ;
Liss, J. .
JOURNAL OF PERINATOLOGY, 2015, 35 (06) :434-438
[2]   MATURATION OF CAFFEINE ELIMINATION IN INFANCY [J].
ARANDA, JV ;
COLLINGE, JM ;
ZINMAN, R ;
WATTERS, G .
ARCHIVES OF DISEASE IN CHILDHOOD, 1979, 54 (12) :946-949
[3]  
BERLIN CM, 1984, PEDIATRICS, V73, P59
[4]   Correlation between plasma and urinary caffeine levels in preterm infants [J].
Cattarossi, Luigi ;
Violino, Marco ;
Macagno, Franco ;
LoGreco, Paolo ;
Savoia, Marilena .
JOURNAL OF PERINATAL MEDICINE, 2006, 34 (04) :344-346
[5]   Caffeine Citrate Treatment for Extremely Premature Infants With Apnea: Population Pharmacokinetics, Absolute Bioavailability, and Implications for Therapeutic Drug Monitoring [J].
Charles, Bruce G. ;
Townsend, Sarah R. ;
Steer, Peter A. ;
Flenady, Vicki J. ;
Gray, Peter H. ;
Shearman, Andrew .
THERAPEUTIC DRUG MONITORING, 2008, 30 (06) :709-716
[6]  
COOK CE, 1976, J PHARMACOL EXP THER, V199, P679
[7]  
desWildt SN, 2001, THER DRUG MONIT, V23, P250
[8]  
Dobson NR., 2013, NeoReviews, V14, pe540, DOI [10.1542/neo.14-11-e540, DOI 10.1542/NEO.14-11-E540]
[9]  
HAECKEL R, 1990, J CLIN CHEM CLIN BIO, V28, P279
[10]  
Henderson-Smart DJ, 2010, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD000140.PUB2